Pathogenesis, prevention, diagnosis and treatment of breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 283-298

  Shah, Rupen ^a   Rosso, Kelly ^a   David Nathanson, S ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Risk factors; Screening; Staging; Surgical management

Indexed keywords

EID: 84921495196     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.283     Document Type: Review

References (115)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, E Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL. Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756 [PMID: 18639491 DOI: 10.1016/S1470-2045(08)70179-7]
3. Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, Carlson RW, Azavedo E, Harford J. Guideline implementation for breast healthcare in low-income and middleincome countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008; 113: 2221-2243 [PMID: 18816619 DOI: 10.1002/cncr.23844]
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
5. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792 [PMID: 16251534 DOI: 10.1056/NEJMoa050518]
6. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Available from: URL: http: //seer. cancer.gov/csr/1975-2005/
7. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr., editors. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH: National Cancer Institute, 2006
8. Buist DS, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, Carney PA, Kerlikowske K, Geller BM. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat 2010; 124: 863-873 [PMID: 20700648]
9. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229-237 [PMID: 16034008 DOI: 10.1056/NEJMoa044383]
10. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258-1265 [PMID: 8435803 DOI: 10.1002/10970142(19930215)71: ]
11. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses health study. Breast Cancer Res Treat 2012; 133: 1097-1104 [PMID: 22350789]
12. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease. Lancet 2001; 358: 1389-1399 [PMID: 11705483 DOI: 10.1016/S0140-6736(01)06524-2]
13. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet 1986; 22: 369-371 [PMID: 3731052 DOI: 10.1016/0165-4608(86)9003 2-4]
14. Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer 2006; 5: 309-321 [PMID: 16858627 DOI: 10.1007/s10689-006-7851-3]
15. Lalloo F, Evans DG. Familial breast cancer. Clin Genet 2012; 82: 105-114 [PMID: 22356477 DOI: 10.1111/j.1399-0004.2012.01859. x]
16. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, Evans DG. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44: 481-484 [PMID: 17369502 DOI: 10.1136/jmg.2007.049346]
17. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689 [PMID: 9497246 DOI: 10.1086/301749]
18. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130 [PMID: 12677558 DOI: 10.1086/375033]
19. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646 [PMID: 14576434 DOI: 10.1126/science. 1088759]
20. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97: 813-822 [PMID: 15928302 DOI: 10.1093/jnci/dji141]
21. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38: 1239-1241 [PMID: 17033622 DOI: 10.1038/ng1902]
22. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 2011; 127: 853-859 [PMID: 21409391 DOI: 10.1007/s10549-011-1443-0]
23. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: Associations and interactions in an international case-control study. Int J Cancer 1990; 46: 796-800 [PMID: 2228308 DOI: 10.1002/ijc.2910460508]
24. Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, Overvad TF, Overvad K, Clavel-Chapelon F, Fournier A, Fagherazzi G, Rohrmann S, Teucher B, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Panico S, Tumino R, Vineis P, Quirós JR, Buckland G, Sánchez MJ, Amiano P, Chirlaque MD, Ardanaz E, Sund M, Lenner P, Bueno-de-Mesquita B, van Gils CH, Peeters PH, Krum-Hansen S, Gram IT, Lund E, Khaw KT, Wareham N, Allen NE, Key TJ, Romieu I, Rinaldi S, Siddiq A, Cox D, Riboli E, Kaaks R. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study. Breast Cancer Res 2012; 14: R76 [PMID: 22583394 DOI: 10.1186/bcr3186]
25. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: The Nurses Health Study. Am J Epidemiol 1994; 139: 819-835 [PMID: 8178795]
26. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-195 [PMID: 12133652 DOI: 10.1016/S0140-6736(02)09454-0]
27. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: The ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009; 18: 169-176 [PMID: 19124495 DOI: 10.1158/1055-9965.EPI-08-0808]
28. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47 [PMID: 8405211]
29. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjønneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, Tormo MJ, Wirfält E, Berglund G, Hallmans G, Key TJ, Reeves G, Bingham S, Norat T, Biessy C, Kaaks R, Riboli E. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004; 111: 762-771 [PMID: 15252848 DOI: 10.1002/ijc.20315]
30. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047-1059 [PMID: 10213546 DOI: 10.1016/S0140-6736(97)08233-0]
31. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. Implementation of the Womens Health Initiative study design. Ann Epidemiol 2003; 13: S5-17 [PMID: 14575938 DOI: 10.1016/S1047-2797(03)00043-7]
32. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses Health Study. Am J Epidemiol 2000; 152: 950-964 [PMID: 11092437 DOI: 10.1093/aje/152.10.950]
33. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in the Womens Health Initiative Observational Study. J Natl Cancer Inst 2013; 105: 526-535 [PMID: 23543779 DOI: 10.1093/jnci/djt043]
34. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366: 1784-1793 [PMID: 16298215 DOI: 10.1016/S0140-6736(05)67725-2]
35. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011; 306: 1884-1890 [PMID: 22045766 DOI: 10.1001/jama.2011.1590]
36. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: A meta-Analysis of prospective studies. Breast Cancer Res Treat 2013; 137: 869-882 [PMID: 23274845 DOI: 10.1007/s10549-012-2396-7]
37. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID, Belfiore A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992; 52: 3924-3930 [PMID: 1617668]
38. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101: 48-60 [PMID: 19116382 DOI: 10.1093/jnci/djn415]
39. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010; 152: 444-455; W144-54 [PMID: 20368650 DOI: 10.7326/0003-4819-152-7-201004060-00009]
40. Guibout C, Adjadj E, Rubino C, Shamsaldin A, Grimaud E, Hawkins M, Mathieu MC, Oberlin O, Zucker JM, Panis X, Lagrange JL, Daly-Schveitzer N, Chavaudra J, de Vathaire F. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23: 197-204 [PMID: 15625374 DOI: 10.1200/JCO.2005.06.225]
41. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168: 1-64 [PMID: 17722996]
42. Pukkala E, Kesminiene A, Poliakov S, Ryzhov A, Drozdovitch V, Kovgan L, Kyyrönen P, Malakhova IV, Gulak L, Cardis E. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer 2006; 119: 651-658 [PMID: 16506213 DOI: 10.1002/ijc.21885]
43. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886 [PMID: 2593165 DOI: 10.1093/jnci/81.24.1879]
44. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14: 103-110 [PMID: 8558184]
45. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358-366 [PMID: 11238697 DOI: 10.1093/jnci/93.5.358]
46. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71 [PMID: 7545954 DOI: 10.1126/science.7545954]
47. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 643-651 [PMID: 8299086 DOI: 10.1002/1097-0142(19940201)73]
48. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003; 40: 807-814 [PMID: 14627668 DOI: 10.1136/jmg.40.11.807]
49. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145-158 [PMID: 9443863 DOI: 10.1086/301670]
50. Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20: 2701-2712 [PMID: 12039933 DOI: 10.1200/JCO.2002.05.121]
51. Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007; 147: 441-450 [PMID: 17909205 DOI: 10.7326/0003-4819-147-7-200710020-00002]
52. James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol 2006; 24: 707-715 [PMID: 16446345 DOI: 10.1200/JCO.2005.01.9737]
53. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002; 94: 844-851 [PMID: 12048272 DOI: 10.1093/jnci/94.11.844]
54. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111-1130 [PMID: 15057881 DOI: 10.1002/sim.1668]
55. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009; 115: 381-390 [DOI: 10.1007/s10549-008-0070-x]
56. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009; 115: 381-390 [PMID: 18516672 DOI: 10.1200/JCO.2010.28.0784]
57. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003; (2): CD003373 [PMID: 12804462 DOI: 10.1002/14651858.CD003373]
58. McCready T, Littlewood D, Jenkinson J. Breast selfexamination and breast awareness: A literature review. J Clin Nurs 2005; 14: 570-578 [PMID: 15840071 DOI: 10.1111/j.1365-2702.2004.01108.x]
59. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.1.2013. Breast Cancer Screening and Diagnosis. Available from: URL: http: //www.nccn.org/professionals/physician-gls/pdf/breast. pdf Accessed: December 8, 2013
60. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971; 215: 1777-1785 [PMID: 5107709 DOI: 10.1001/jama.1971.0318024 0027005]
61. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 1977; 39: 2772-2782 [PMID: 326378 DOI: 10.1002/1097-0142(197706)39: ]
62. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study: A randomized trial with breast cancer screening. Natl Cancer Inst Monogr 1985; 67: 65-74 [PMID: 4047153]
63. Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol 2004; 33: 43-55 [PMID: 15075144 DOI: 10.1093/ije/dyg275]
64. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 727-37, W237-42 [PMID: 19920273 DOI: 10.7326/0003-4819-1 51-10-200911170-00009]
65. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-Term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-919 [PMID: 11918907 DOI: 10.1016/S0140-6736(02)08020-0]
66. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013; 6: CD001877 [PMID: 23737396 DOI: 10.1002/14651858. CD001877.pub5]
67. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148: 671-679 [PMID: 18458280 DOI: 10.7326 /0003-4819-148-9-200805060-00007]
68. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437 [PMID: 15282350 DOI: 10.1056/NEJMoa031759]
69. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299: 2151-2163 [PMID: 18477782 DOI: 10.1001/jama.299.18.2151]
70. Kelly KM, Dean J, Comulada WS, Lee SJ. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol 2010; 20: 734-742 [PMID: 19727744 DOI: 10.1007/s00330-009-1588-y]
71. Gartlehner G, Thaler K, Chapman A, Kaminski-Hartenthaler A, Berzaczy D, Van Noord MG, Helbich TH. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev 2013; 4: CD009632 [PMID: 23633376 DOI: 10.1002/14651858.CD009632.pub2]
72. Smetherman DH. Screening, imaging, and image-guided biopsy techniques for breast cancer. Surg Clin North Am 2013; 93: 309-327 [PMID: 23464688 DOI: 10.1016/j.suc.2013.01.004]
73. American College of Radiology. Breast imaging reporting and data system (BI-RADS). 4th ed. Reston (VA): American College of Radiology, 2003
74. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, OMalley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978 [PMID: 10888772]
75. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134: e48-e72 [PMID: 20586616 DOI: 10.1043/1543-2165-134.7.e48]
76. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168 [PMID: 9504686]
77. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor testing in breast cancer. J Clin Oncol 2007; 25: 118-145 [PMID: 17159189 DOI: 10.1200/JCO.2006.09.2775]
78. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008; 129: 263-273 [PMID: 18208807 DOI: 10.1309 /99AE032R9FM8WND1]
79. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826 [PMID: 15591335 DOI: 10.1056/NEJMoa041588]
80. van de Vijver MJ, He YD, vant Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009 [PMID: 12490681 DOI: 10.1056/NEJMoa021967]
81. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-575 [PMID: 12192016 DOI: 10.1056/NEJMoa020128]
82. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241 [PMID: 12393820 DOI: 10.1056/NEJMoa022152]
83. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391-395 [PMID: 1984541 DOI: 10.1001/jama.1991.03460030097037]
84. Houssami N, Macaskill P, Marinovich ML, Dixon JM, Irwig L, Brennan ME, Solin LJ. Meta-Analysis of the impact of surgical margins on local recurrence in women with earlystage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 2010; 46: 3219-3232 [PMID: 20817513 DOI: 10.1016/j.ejca.2010.07.043]
85. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785 [PMID: 18258986 DOI: 10.1200/JCO.2007.15.0235]
86. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106 [PMID: 16360786 DOI: 10.1016/S0140-6736(05)67887-7]
87. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-Analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716 [PMID: 22019144 DOI: 10.1016/S0140-6736(11)61629-2]
88. Dershaw DD, McCormick B, Osborne MP. Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 1992; 70: 493-496 [PMID: 1617598 DOI: 10.1002 /1097-0142(19920715)70: ]
89. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011; 18: 2851-2857 [PMID: 21442348 DOI: 10.1245/s10434-011-1665-8]
90. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-1691 [PMID: 20194857 DOI: 10.1200/JCO.2009.24.9284]
91. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684 [PMID: 16236738 DOI: 10.1056/NEJMoa052122]
92. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-1683 [PMID: 20065188 DOI: 10.1200/JCO.2009.23.7610]
93. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553 [PMID: 12904519 DOI: 10.1056/NEJMoa012782]
94. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, De Cicco C, Vezzoli D. Sentinel lymph node biopsy in breast cancer: Ten-year results of a randomized controlled study. Ann Surg 2010; 251: 595-600 [PMID: 20195151 DOI: 10.1097/SLA.0b013e3181c0e92a]
95. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18: 2553-2559 [PMID: 10893286]
96. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011; 305: 569-575 [PMID: 21304082 DOI: 10.1001/jama.2011.90]
97. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717 [PMID: 15894097 DOI: 10.1016/S0140-6736(05)66544-0]
98. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes. Tumori 1978; 64: 241-258 [PMID: 675854]
99. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995; 45: 199-226 [PMID: 7600278 DOI: 10.3322/canjclin.45.4.199]
100. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983 [PMID: 12637460 DOI: 10.1200/JCO.2003.02.063]
101. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696 [PMID: 15897552 DOI: 10.1200/JCO.2005.10.517]
102. De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-Analysis of randomized trials. J Clin Oncol 2008; 26: 44-53 [PMID: 18165639 DOI: 10.1200/JCO.2007.11.3787]
103. Network NCC. National Cancer Comprehensive Network (NCCN), Breast Cancer Panel (BCP). NCCN Practice Guidelines in Oncology, Breast Cancer. NCCN, 2008
104. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874 [PMID: 11553815 DOI: 10.1073/pnas.191367098]
105. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752 [PMID: 10963602 DOI: 10.1038/35021093]
106. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376 [PMID: 18316557 DOI: 10.1158/1078-0432.CCR-07-1658]
107. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750 [PMID: 19436038 DOI: 10.1093/jnci/djp082]
108. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-1810 [PMID: 14584060 DOI: 10.1002/cncr.11745]
109. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141 [PMID: 21087898 DOI: 10.1016/S1470-2045(10)70257-6]
110. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review. Gene 1995; 159: 19-27 [PMID: 7607568 DOI: 10.1016/0378-1119(94)00866-Q]
111. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-244 [PMID: 21354370 DOI: 10.1016/S1470-2045(11)70033-X]
112. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283 [PMID: 21991949 DOI: 10.1056/NEJMoa0910383]
113. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-Analysis and systematic review. J Clin Oncol 2004; 22: 4010-4018 [PMID: 15459225 DOI: 10.1200/JCO.2004.06.080]
114. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, Lawton T, Conant EF, Orel SG, Schuchter L, Fox KR, Zieber N, Glick JH, Solin LJ. The impact of a multidisciplinary breast cancer center on recommendations for patient management: The University of Pennsylvania experience. Cancer 2001; 91: 1231-1237 [PMID: 11283921 DOI: 10.1002/1 097-0142(20010401)91: ]
115. Gabel M, Hilton NE, Nathanson SD. Multidisciplinary breast cancer clinics. Do they work? Cancer 1997; 79: 2380-2384 [PMID: 9191526 DOI: 10.1002/(SICI)1097-0142]